Comparable stake leader
Ikarian Capital, LLC
SEC ownership of CNS Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001729427.
Disclosed value leader
Ikarian Capital, LLC
Comparable rows
13/27
Latest evidence
14 Aug 2026
- Public ticker
- CNSP on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Ikarian Capital, LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
13 of 27
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Ikarian Capital, LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
14 Aug 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001729427
- Issuer location
- Houston, TX
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of CNS Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Ikarian Capital, LLC
Disclosed value leader
Ikarian Capital, LLC
Comparable rows
13/27
Latest evidence
14 Aug 2026
13D/G
13F
3/4/5
Lead comparable stake: 9.9%
14 rows are not safely comparable across share classes.
13D/G row: Ikarian Capital, LLC
Showing 1-8 of 27 holder rows.
Quick read
Ikarian Capital, LLC leads the comparable SEC ownership view at 9.9%.
13 of 27 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Ikarian Capital, LLC's linked filing trail.
Comparable ownership
Top 5
Ikarian Capital, LLC
9.9%
Stonepine Capital Management, LLC
9.9%
ARMISTICE CAPITAL, LLC
5%
Michal Fisher
0.13%
ADAR1 Capital Management, LLC
4.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 27 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Ikarian Capital, LLC |
13D/G
13F
Company
|
9.9%
|
$749,706
147,290 shares
|
+$516,431 | 30 Jun 2026 |
| Stonepine Capital Management, LLC |
13D/G
13F
Company
|
9.9%
|
$402,671
159,790 shares
|
+$279,627 | 31 Mar 2026 |
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
|
$5,432
30,177 shares
|
-$95,575 | 30 Sep 2025 |
| Michal Fisher |
3/4/5
Director
|
0.13%
|
$10,000
2,000 shares
|
+$10,000 | 18 May 2026 |
| ADAR1 Capital Management, LLC |
13F
Company
|
4.7%
|
$334,600
70,000 shares
|
— | 30 Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
Company
|
0.91%
|
$64,645
13,524 shares
|
— | 30 Jun 2026 |
| VANGUARD FIDUCIARY TRUST CO |
13F
Company
|
0.69%
|
$48,880
10,226 shares
|
— | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
0.47%
|
$33,427
6,993 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$44,002.
Buys
$44,002
Insiders: 2
Sells
$0
Insiders: 0
Net
+$44,002
Shares: +9,100
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 9,100
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 9,100 | 0 | $44,002 | $0 | +$44,002 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-15 of 15 reporting-owner rows connected to CNS Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
15
Largest Forms 3/4/5 holder
Waldemar Priebe
Net 12M change
+$44,002
Latest report
14 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Waldemar Priebe | 10%+ Owner | $198,486 | Mixed | 06 Dec 2022 | ||
| Cortice Biosciences, Inc. | 10%+ Owner | $172,010 | Mixed | 30 Jul 2024 | ||
| Carl Anthony Evans | Director | $54,165 | Mixed | 08 Apr 2024 | ||
| Faith L. Charles | Director | $34,001 | +$34,002 | +100% | Filing P/S | 18 May 2026 |
| Rami Levin | CEO and President | $22,705 | Median | 14 Aug 2026 | ||
| Michal Fisher | Director | $10,000 | +$10,000 | +100% | Filing P/S | 18 May 2026 |
| Christopher Downs | Chief Financial Officer | Mixed | 17 Nov 2025 | |||
| Steve O'Loughlin | Chief Financial Officer | Mixed | 02 Mar 2026 | |||
| Eric Faulkner | Chief Technology Officer | Mixed | 02 Mar 2026 | |||
| Jerzy Gumulka | Director | Mixed | 17 Nov 2025 | |||
| Bettina M. Cockroft | Director | Mixed | 17 Nov 2025 | |||
| John M. Climaco | Chief Executive Officer, Director | Mixed | 17 Nov 2025 | |||
| Jeffry R. Keyes | Director | Mixed | 17 Nov 2025 | |||
| Amy Mahery | Director | Mixed | 17 Nov 2025 | |||
| Andrzej Andraczke | Director | Mixed | 21 Sep 2023 |
Recent insider transactions for CNS Pharmaceuticals, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Rami Levin | CNSP | Common Stock | Options Exercise | -50% | -4,750 | 4,750 | 14 Aug 2026 | Direct | ||
| Rami Levin | CNSP | Restricted Stock Units | Options Exercise | -25% | -4,750 | 14,250 | 14 Aug 2026 | Direct | ||
| Michal Fisher | CNSP | Common Stock | Purchase | $10,000 | $5.00 | 2,000 | 2,000 | 18 May 2026 | Direct | |
| Faith L. Charles | CNSP | Common Stock | Purchase | $34,002 | $4.79 | 7,100 | 7,100 | 18 May 2026 | Direct | |
| Eric Faulkner | CNSP | Restricted Stock Units | Award | 9,500 | 9,500 | 02 Mar 2026 | Direct | |||
| Steve O'Loughlin | CNSP | Restricted Stock Units | Award | 9,500 | 9,500 | 02 Mar 2026 | Direct | |||
| Rami Levin | CNSP | Restricted Stock Units | Award | 19,000 | 19,000 | 01 Jan 2026 | Direct | |||
| Jeffry R. Keyes | CNSP | Option to purchase common stock | Award | 1,517 | 1,517 | 17 Nov 2025 | Direct | |||
| Bettina M. Cockroft | CNSP | Option to purchase common stock | Award | 1,517 | 1,517 | 17 Nov 2025 | Direct | |||
| John M. Climaco | CNSP | Option to purchase common stock | Award | 9,761 | 9,761 | 17 Nov 2025 | Direct | |||
| Amy Mahery | CNSP | Option to purchase common stock | Award | 1,517 | 1,517 | 17 Nov 2025 | Direct | |||
| Faith L. Charles | CNSP | Option to purchase common stock | Award | 1,517 | 1,517 | 17 Nov 2025 | Direct | |||
| Christopher Downs | CNSP | Option to purchase common stock | Award | 4,881 | 4,881 | 17 Nov 2025 | Direct | |||
| Jerzy Gumulka | CNSP | Option to purchase common stock | Award | 1,517 | 1,517 | 17 Nov 2025 | Direct |
* marks a reported price that did not pass the local price check.